Print
19 September 2017
GMP News
Clinical trials of about 30 new medicinal products for the treatment of cancer, autoimmune and hereditary diseases are expected to start in the Russian Federation. This was announced by the Russian Minister of Health Veronika Skvortsova at Biotechmed, a specialized conference.
“We already have 30 medicines that are being prepared for clinical trials and are designed to treat diseases requiring immunocorrection. First of all, this includes cancer, autoimmune diseases, allergic diseases, and hereditary diseases, including neurodegenerative and neuromuscular disorders,” said the minister.
She added that safety is an issue of fundamental importance, because “everything that is tested for humans is tested in humans.”
“It is not uncommon that out of 100 million molecules theory-based selected at the very beginning, only one medicinal product actually reaches the humans. And just 10 molecules enter the phase of clinical trials,” said the minister.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.